Pembrolizumab-Induced Lichenoid Dermatitis in a Patient With Metastatic Cancer of Unknown Primary

Pembrolizumab is an immune checkpoint inhibitor approved for use in many cancer types such as non-small cell lung cancer (NSCLC), metastatic melanoma, head and neck cancers, hepatocellular carcinoma, and renal cell carcinoma. There are many reported cases of patients on immunotherapy who have discon...

Descripción completa

Detalles Bibliográficos
Autores principales: Sethi, Ashish, Raj, Moses
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2021
Materias:
Dermatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8026086/
https://www.ncbi.nlm.nih.gov/pubmed/33842144
http://dx.doi.org/10.7759/cureus.13768

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8026086/
https://www.ncbi.nlm.nih.gov/pubmed/33842144
http://dx.doi.org/10.7759/cureus.13768

Ejemplares similares